Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells

Cancer Letters

Volumn 315, Issue 2, 2012, Pages 198-205

  Huang, Shuling ^a   Chen, Min ^a   Shen, Yonghua ^a   Shen, Weidong ^a   Guo, Huimin ^a   Gao, Qian ^a   Zou, Xiaoping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Chemotherapy; Gastric cancer; Multidrug resistance; Stat3

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CISPLATIN; PROTEIN P53; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; BCL 2 GENE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMANS; POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 84355161519     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.011     Document Type: Article

References (38)

1. Ajani J.A. Chemotherapy for gastric carcinoma: new and old options. Oncology 1998, 12:44-47.
2. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
3. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
4. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hemat. 2007, 63:12-31.
5. Barre B., Vigneron A., Perkins N., Roninson I.B., Gamelin E., Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 2007, 13:4-11.
6. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
7. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
8. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernández-Luna J.L., Nu ez G. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
9. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:9-11.
10. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M.P., Zellweger T., Alanen K., Mirtti T. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 2008, 172:1717-1728.
11. Leeman-Neill R.J., Wheeler S.E., Singh S.V., Thomas S.M., Seethala R.R., Neill D.B., Panahandeh M.C., Hahm E.R., Joyce S.C., Sen M. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009, 30:1848-1856.
12. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., Hampel C., Lee H., Seiden M.V. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 2006, 12:5055-5063.
13. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
14. Yang C., Hornicek F.J., Wood K.B., Schwab J.H., Choy E., Mankin H., Duan Z. Blockage of Stat3 With CDDO-Me inhibits tumor cell growth in chordoma. Spine 2010, 35:1668-1675.
15. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., Ichikawa H. Targeting signal transducer and activator of transcription 3 for prevention and therapy of cancer. Ann. New York Acad. Sci. 2006, 1091:151-169.
16. Fletcher S., Turkson J., Gunning P.T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008, 3:1159-1168.
17. Rebbaa A. Targeting senescence pathways to reverse drug resistance in cancer. Cancer Lett. 2005, 219:1-13.
18. Oliver T.G., Mercer K.L., Sayles L.C., Burke J.R., Mendus D., Lovejoy K.S., Cheng M.H., Subramanian A., Mu D., Powers S. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010, 24:837-852.
19. Metzinger D.S., Taylor D.D., Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett. 2006, 236:302-308.
20. Chen M., Zou X., Luo H., Cao J., Zhang X., Zhang B., Liu W. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol. Int. 2009, 33:1008-1019.
21. Pérez-Sayáns M., Somoza-Martín J.M., Barros-Angueira F., Diz P.G., Rey J.M.G., García-García A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. Cancer Lett. 2010, 295:135-143.
22. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987, 47:414-418.
23. Niu G., Wright K.L., Ma Y., Wright G.M., Huang M., Irby R., Briggs J., Karras J., Cress W.D., Pardoll D. Role of Stat3 in regulating p53 expression and function. Mol. Cell Biol. 2005, 25:7432-7440.
24. Konnikova L., Simeone M.C., Kruger M.M., Kotecki M., Cochran B.H. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 2005, 65:6516-6520.
25. Ikuta K., Takemura K., Kihara M., Nishimura M., Ueda N., Naito S., Lee E., Shimizu E., Yamauchi A. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol. Rep. 2005, 13:217-222.
26. Gariboldi M.B., Ravizza R., Molteni R., Osella D., Gabano E., Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007, 258:181-188.
27. Nielsen M., Kaestel C.G., Eriksen K.W., Woetmann A., Stokkedal T., Kaltoft K., Geisler C., R pke C., Odum N. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999, 13:735-738.
28. Uehara Y., Mochizuki M., Matsuno K., Haino T., Asai A. Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem. Biophys. Res. Commun. 2009, 380:627-631.
29. Quintanilla-Martinez L., Kremer M., Specht K., Calzada-Wack J., Nathrath M., Schaich R., Hofler H., Fend F. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am. J. Pathol. 2003, 162:1449-1461.
30. Kim D.K., Oh S.Y., Kwon H.C., Lee S., Kwon K.A., Kim B.G., Kim S.G., Kim S.H., Jang J.S., Kim M.C. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009, 9:155.
31. Yang C., Schwab J.H., Schoenfeld A.J., Hornicek F.J., Wood K.B., Nielsen G.P., Choy E., Mankin H., Duan Z. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol. Cancer Ther. 2009, 8:2597-2605.
32. Lo H.W., Cao X., Zhu H., Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res. 2008, 14:6042-6054.
33. Poeta G.D., Bruno A., Del Principe M.I., Venditti A., Maurillo L., Buccisano F., Stasi R., Neri B., Luciano F., Siniscalchi A. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr. Cancer Drug Tar. 2008, 8:207-222.
34. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., Marra M., Lugini L., Logozzi M., Lozupone F. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 2004, 96:1702-1713.
35. Gao Q., Wolfgang M.J., Neschen S., Morino K., Horvath T.L., Shulman G.I., Fu X.Y. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci 2004, 101:4661-4666.
36. Inoue H., Ogawa W., Ozaki M., Haga S., Matsumoto M., Furukawa K., Hashimoto N., Kido Y., Mori T., Sakaue H., Teshigawara K., Jin S., Iguchi H., Hiramatsu R., LeRoith D., Takeda K., Akira S., Kasuga M. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
37. Nie Y., Erion D.M., Yuan Z., Dietrich M., Shulman G.I., Horvath T.L., Gao Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol. 2009, 11:492-500.
38. Leslie K., et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006, 66:2544-2552.